Envoy Medical®, Inc. (NASDAQ: COCH), a hearing health company, recently announced it has selected seven study sites for participation in its pivotal clinical trial to investigate its first-of-its-kind fully implanted Acclaim ® cochlear implant (Acclaim CI). Initial patient enrollment is anticipated to begin during the first quarter of 2025.
Envoy Medical is a leading medical device company focused on providing innovative technologies across the hearing loss spectrum. According to the National Institute of Deafness and Other Communication Disorders, 13% of people in the U.S. ages 12 years and older have hearing loss in both ears. This showcases the widespread nature of hearing loss.
The Acclaim CI is currently differentiated from other cochlear implants in that it is designed to: (1) be fully implanted with no external components attached to the side of the head, (2) leverage the natural anatomy of the ear to pick up sound rather than rely on an external or sub-dermal microphone, (3) allow for all day hearing, and (4) have a battery lasting multiple days between recharge.
